Cargando…

Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization

Pancreatic cancer rapidly acquires resistance to chemotherapy resulting in its being difficult to treat. Gemcitabine is the current clinical chemotherapy strategy; however, owing to gemcitabine resistance, it is only able to prolong the life of patients with pancreatic cancer for a limited number of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Tao, Li, Hai-Ying, Wu, Jian-Song, Niu, Qiang, Duan, Wei-Hong, Han, Qing-Zeng, Ji, Wang-Ming, Zhang, Tao, Lv, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652142/ https://www.ncbi.nlm.nih.gov/pubmed/29098031 http://dx.doi.org/10.3892/ol.2017.6836

Ejemplares similares

Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters
por: Wu, Ying-Si, et al.
Publicado: (2021)

Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway
por: Namba, T, et al.
Publicado: (2015)

Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine
por: Yin, Tao, et al.
Publicado: (2016)

Up‐regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine‐resistant pancreatic cancer cells
por: Zhao, Hengqiang, et al.
Publicado: (2017)

Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
por: Gong, Dao-Jun, et al.
Publicado: (2013)

OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer
por: Baylot, V, et al.
Publicado: (2011)

Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway
por: Zhang, Tianli, et al.
Publicado: (2022)

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation
por: Li, Junjie, et al.
Publicado: (2018)

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway
por: Zhou, Yunjiang, et al.
Publicado: (2019)

High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma
por: Lv, Wei, et al.
Publicado: (2016)

miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis
por: Yang, Rui-Meng, et al.
Publicado: (2017)

Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine
por: Li, Hua, et al.
Publicado: (2017)

Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
por: Fraunhoffer, Nicolas Alejandro, et al.
Publicado: (2022)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis
por: Yu, Shuo, et al.
Publicado: (2021)

Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer
por: Venkatasubbarao, Kolaparthi, et al.
Publicado: (2013)

Gemcitabine inhibits immune escape of pancreatic cancer by down regulating the soluble ULBP2 protein
por: Lin, Xiansheng, et al.
Publicado: (2016)

Gemcitabine Conjugated Chitosan and Double Antibodies (Abc-GC-Gemcitabine Nanoparticles) Enhanced Cytoplasmic Uptake of Gemcitabine and Inhibit Proliferation and Metastasis In Human SW1990 Pancreatic Cancer Cells
por: Xiao, Jun, et al.
Publicado: (2017)

P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer
por: Ono, Hiroaki, et al.
Publicado: (2016)

Metformin Inhibits Gemcitabine Induced Apoptosis in Pancreatic Cancer Cell Lines
por: Zechner, Dietmar, et al.
Publicado: (2017)

microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer
por: Funamizu, Naotake, et al.
Publicado: (2023)

Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P-glycoprotein and MRPs expression
por: Guo, Hongchun, et al.
Publicado: (2020)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

LW6 enhances chemosensitivity to gemcitabine and inhibits autophagic flux in pancreatic cancer
por: Zhang, Xianbin, et al.
Publicado: (2019)

Fibroblast inhibition by tocilizumab enabled gemcitabine/nab‐paclitaxel rechallenge for pancreatic cancer
por: Mitsunaga, Shuichi, et al.
Publicado: (2023)

YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine
por: Jiang, Zhengdong, et al.
Publicado: (2016)

Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine
por: Nakai, Y, et al.
Publicado: (2010)

Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine
por: DUONG, HONG-QUAN, et al.
Publicado: (2013)

STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer
por: Liu, Chao, et al.
Publicado: (2019)

Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment
por: Rimmer, Ella, et al.
Publicado: (2022)

Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy
por: Chen, Yang, et al.
Publicado: (2017)

Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
por: Lu, Jun, et al.
Publicado: (2023)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
por: Ouyang, Guoqing, et al.
Publicado: (2016)

Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine
por: Yu, Yue, et al.
Publicado: (2019)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo
por: Zhi, Xiao, et al.
Publicado: (2015)

Gemcitabine-Loaded Albumin Nanoparticle Exerts An Antitumor Effect on Gemcitabine-Resistant Pancreatic Cancer Cells Induced by MDR1 and MRP1 Overexpression in Vitro
por: Kong, Lei, et al.
Publicado: (2022)

Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer
por: Phan, Thuy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n35p9d5pclfoss7debmqt1pf1k